Pennant Biotechnology

Pennant Therapeutics is a pre-clinical stage biotechnology company focused on developing novel therapies for life-threatening conditions characterized by vascular leak and excessive inflammation. The company's primary research centers on the inhibition of Myosin Light Chain Kinase (MLCK) to restore endothelial barrier function and prevent organ failure. Their lead programs target Acute Respiratory Distress Syndrome (ARDS) and other inflammatory disorders where maintaining vascular integrity is critical. By leveraging proprietary small molecule and peptide inhibitors, Pennant aims to provide first-in-class treatments for high-unmet-need critical care and chronic inflammatory indications.